Two new four-drug TB regimens show potential in phase 2 trial; review finds gaps in testing of lung cancer AI tools; CT screening tied to earlier SCLC

An incentive spirometer with a clear chamber and piston marked only with plain tick marks, a slim side column with a float, and a mouthpiece on a ribbed hose.

Regimens built on ganfeborole and BTZ-043 showed evidence of potential efficacy against tuberculosis in the phase 2 PARADIGM4TB trial, published Nov. 19 in the New England Journal of Medicine. A NEJM AI review found gaps in how lung cancer AI tools are tested, CT screening was tied to earlier-stage small cell lung cancer, and the Food and Drug Administration (FDA) issued alerts on needle-free valves and vascular guidewires.

  • Research Nov 19, 2026
    In the phase 2 PARADIGM4TB trial, published online Nov. 19 in the New England Journal of Medicine, 401 participants with tuberculosis were randomized to standard isoniazid-rifampin-pyrazinamide-ethambutol (HRZE) for 24 weeks or new four-drug regimens for 16 weeks. On the primary end point, the log10(time to positivity) slope, the relative difference versus HRZE was 20.5% (95% credible interval 2.7 to 41.1) for BTZ-043-bedaquiline-delamanid-moxifloxacin and 9.1% (95% credible interval -8.6 to 29.0) for ganfeborole-bedaquiline-pretomanid-moxifloxacin, with posterior probabilities of superiority of 0.99 and 0.83. Grade 3 or higher adverse events occurred in 28%, 38% and 24% of the BTZ-043, ganfeborole and HRZE groups.
  • AI Nov 16, 2026
    A meta-research review in NEJM AI, published online Nov. 16, examined statistical practices in 36 studies of image-reliant AI tools that predict lung cancer outcomes. Common limitations included limited external test set use in 14 studies (39%) and insufficient subgroup analyses in 10 (28%). The authors said future research should prioritize standardized reporting and use of external test sets.
    Sources: NEJM AI, PubMed
  • Research Nov 19, 2026
    A retrospective study of Medicare data linked to Surveillance, Epidemiology, and End Results registry data, published online Nov. 19 in JAMA Oncology, included 17,099 patients with small cell lung cancer, 949 of them in a screened group. Distant disease was diagnosed in 44.2% of screened versus 70.4% of unscreened patients (P < .001), and three-year overall survival was 28.0% versus 10.8% (P < .001). The authors described screening as associated with a shift toward earlier-stage disease at diagnosis.
  • FDA Nov 19, 2026
    The Food and Drug Administration (FDA) issued an early alert Nov. 19 on the B. Braun Caresite Micro Luer Access Device after the company found a depressed piston can cause backflow and leakage, with reports of air ingress through valves that remained open after disconnection. Patients at greatest risk may include neonates, pediatric patients and critically ill patients, and severe air embolism may cause serious injury and, rarely, death, according to the FDA. Clinicians are told to inspect the devices after disconnecting a male luer connector; as of Nov. 3, the company had reported no serious injuries or deaths.
    Source: FDA
  • Research Nov 17, 2026
    A national target trial emulation of 20,627 lung transplants, 1,419 (7%) with ex vivo lung perfusion allografts, was published online Nov. 17 in Annals of Surgery. Among recipients in the Composite Allocation Score era, the technique was associated with similar outcomes at high-volume centers but higher two-year mortality at other centers (hazard ratio 2.43, 95% CI 1.36 to 4.34; P = .003) and allograft failure (hazard ratio 2.52, 95% CI 1.31 to 4.84; P = .005).
  • FDA Nov 20, 2026
    The Food and Drug Administration (FDA) issued an early alert Nov. 20 on Navilyst, Spectrum and Arrow Marked vascular guidewires from Heraeus Medevio, which are indicated for percutaneous entry of peripheral vessels using the Seldinger technique. Clumping of the hydrophilic coating raises the potential for flaking, displacement or detachment, and reported consequences of such embolization include vascular occlusion, stroke, organ failure and death, according to the FDA. Users were told to immediately cease use of affected products; Heraeus has reported no serious injuries or deaths.
    Source: FDA

The weekly innovation roundup for pulmonary and critical care, published every Sunday for the week before; every item links to its sources. Latest pulmonary and critical care news · All specialties

Latest news

Tagged pulmonary and critical care, from the daily briefing

  1. Real-world outcomes of adding a long-acting beta-agonist to inhaled corticosteroids in preschool children with asthma
  2. Lancet Respiratory Medicine reviews the 2027 GOLD report on COPD
  3. ALNEO phase 2 trial reports neoadjuvant alectinib before surgery in resectable stage III ALK-positive lung cancer

See all the latest news